Business Context and Reporting Period
Company: Silexion Therapeutics Corp (SLXN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 23, 2025
Reporting Period: The filing addresses events occurring on May 22, 2025, regarding the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a notice of delisting and does not contain a financial statement. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Relevant Listing Standards Referenced:
- Market Value of Listed Securities (MVLS): Required minimum of $50,000,000 (Nasdaq Global Market).
- Market Value of Publicly Held Shares (MVPHS): Required minimum of $15,000,000 (Nasdaq Global Market).
- Shareholders' Equity: Required minimum of $2.5 million for transfer to the Nasdaq Capital Market.
Material Changes
Delisting Notice: On May 22, 2025, the Company received a formal delisting notice from the Nasdaq Listing Qualifications Department.
Deficiencies: The Company failed to regain compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C) within the granted 180-day compliance period (ending May 19, 2025). Specifically:
- MVLS closed below $50,000,000 for 30 consecutive business days prior to November 19, 2024.
- MVPHS closed below $15,000,000 for 30 consecutive business days prior to November 19, 2024.
Consequences: If the appeal is unsuccessful, trading of ordinary shares (SLXN) and warrants (SLXNW) will be suspended at the opening of business on June 2, 2025, followed by removal from Nasdaq listing.
Guidance, Outlook, and Risks
Management Action Plan:
- Appeal: The Company intends to request an appeal before the Nasdaq Hearings Panel by May 29, 2025.
- Transfer Strategy: As part of the appeal, the Company plans to apply to transfer its listing to the Nasdaq Capital Market.
Outlook and Uncertainties:
- There is no assurance that the appeal will be successful.
- There is no assurance that the Company can meet the Equity Standard ($2.5 million shareholders' equity) required for the Nasdaq Capital Market within any additional time period granted.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual events may differ materially due to the potential failure of the appeal or the inability to meet equity standards.
Investor Verification Checklist
- Verify the outcome of the appeal request to be submitted by May 29, 2025.
- Confirm the Company's current shareholders' equity to assess eligibility for the Nasdaq Capital Market ($2.5 million threshold).
- Monitor for a Form 25-NSE filing, which would confirm the removal of securities from Nasdaq if the appeal fails.
- Review the Company's most recent Form 10-K (filed March 18, 2025) for detailed risk factors and financial position.